WO2009071613A3 - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
WO2009071613A3
WO2009071613A3 PCT/EP2008/066762 EP2008066762W WO2009071613A3 WO 2009071613 A3 WO2009071613 A3 WO 2009071613A3 EP 2008066762 W EP2008066762 W EP 2008066762W WO 2009071613 A3 WO2009071613 A3 WO 2009071613A3
Authority
WO
WIPO (PCT)
Prior art keywords
viral vector
seq
protein
relates
vector
Prior art date
Application number
PCT/EP2008/066762
Other languages
French (fr)
Other versions
WO2009071613A2 (en
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Joseph D Cohen
Martine Marchand
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009071613(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to MX2010006207A priority Critical patent/MX2010006207A/en
Priority to CN2008801267101A priority patent/CN101939438A/en
Priority to AP2010005295A priority patent/AP2010005295A0/en
Priority to BRPI0819889-6A priority patent/BRPI0819889A2/en
Priority to AU2008333208A priority patent/AU2008333208A1/en
Application filed by Glaxosmithkline Biolog Sa, Joseph D Cohen, Martine Marchand filed Critical Glaxosmithkline Biolog Sa
Priority to CA2707245A priority patent/CA2707245A1/en
Priority to JP2010536451A priority patent/JP2011505796A/en
Priority to EP08857977A priority patent/EP2227550A2/en
Publication of WO2009071613A2 publication Critical patent/WO2009071613A2/en
Publication of WO2009071613A3 publication Critical patent/WO2009071613A3/en
Priority to IL205953A priority patent/IL205953A0/en
Priority to ZA2010/03851A priority patent/ZA201003851B/en
Priority to MA32991A priority patent/MA32003B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to a replication deficient simian adenoviral vector C7 encoding a protein comprising CS protein from P. falciparum or a fragment thereof, for example as shown in Seq ID No: 1 or Seq ID No: 3. The invention also relates to processes of preparing said viral vector and use of the viral vector in the treatment/prevention of malaria infection. Compositions, vaccines and kits comprising said viral vector are also described. In one aspect the invention employs a synthetic C7 viral vector. The C7 viral vector according to the invention may be co-administered or co-formulated with a malaria antigen such as RTS,S optionally in the presence of an adjuvant for example comprising 3D-MPL and/or a saponin such as QS21.
PCT/EP2008/066762 2007-12-06 2008-12-04 Vaccine WO2009071613A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP08857977A EP2227550A2 (en) 2007-12-06 2008-12-04 Vaccine
JP2010536451A JP2011505796A (en) 2007-12-06 2008-12-04 vaccine
AP2010005295A AP2010005295A0 (en) 2008-12-04 2008-12-04 Vaccine
BRPI0819889-6A BRPI0819889A2 (en) 2007-12-06 2008-12-04 Viral vector, composition, vaccine, vaccine composition, kit, processes for the preparation of a viral vector and for the preparation of a composition, use of a viral vector, and method of treatment
AU2008333208A AU2008333208A1 (en) 2007-12-06 2008-12-04 Vaccine
MX2010006207A MX2010006207A (en) 2007-12-06 2008-12-04 Vaccine.
CA2707245A CA2707245A1 (en) 2007-12-06 2008-12-04 Vaccine
CN2008801267101A CN101939438A (en) 2007-12-06 2008-12-04 Vaccine
IL205953A IL205953A0 (en) 2007-12-06 2010-05-25 Vaccine
ZA2010/03851A ZA201003851B (en) 2007-12-06 2010-05-28 Vaccine
MA32991A MA32003B1 (en) 2007-12-06 2010-07-05 Vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06
US60/992,802 2007-12-06

Publications (2)

Publication Number Publication Date
WO2009071613A2 WO2009071613A2 (en) 2009-06-11
WO2009071613A3 true WO2009071613A3 (en) 2009-08-13

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/066762 WO2009071613A2 (en) 2007-12-06 2008-12-04 Vaccine

Country Status (20)

Country Link
EP (1) EP2227550A2 (en)
JP (1) JP2011505796A (en)
KR (1) KR20100108544A (en)
CN (1) CN101939438A (en)
AR (1) AR069568A1 (en)
AU (1) AU2008333208A1 (en)
BR (1) BRPI0819889A2 (en)
CA (1) CA2707245A1 (en)
CL (1) CL2008003614A1 (en)
CO (1) CO6300795A2 (en)
CR (1) CR11537A (en)
DO (1) DOP2010000164A (en)
IL (1) IL205953A0 (en)
MA (1) MA32003B1 (en)
MX (1) MX2010006207A (en)
PE (1) PE20091106A1 (en)
TW (1) TW200938633A (en)
UY (1) UY31510A1 (en)
WO (1) WO2009071613A2 (en)
ZA (1) ZA201003851B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
EA027236B1 (en) * 2011-04-08 2017-07-31 Иммьюн Дизайн Корп. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN110687289B (en) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Application of FGL2 protein as malaria infection marker

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
WO2005071093A2 (en) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
WO2006040334A1 (en) * 2004-10-14 2006-04-20 Crucell Holland B.V. Malaria prime/boost vaccines
US20060188527A1 (en) * 2002-10-23 2006-08-24 Hoffman Stephen L Methods for vaccinating against malaria
WO2007003384A1 (en) * 2005-06-30 2007-01-11 Glaxosmithkline Biologicals Sa Anti-malaria vaccine
US20070071726A1 (en) * 2002-12-17 2007-03-29 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008009650A2 (en) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
WO2008107370A1 (en) * 2007-03-02 2008-09-12 Glaxosmithkline Biologicals S.A. Novel method and compositions
WO2008122811A2 (en) * 2007-04-10 2008-10-16 Isis Innovation Ltd Adenoviral vectors encoding a pathogen or tumour antigen

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
US20060188527A1 (en) * 2002-10-23 2006-08-24 Hoffman Stephen L Methods for vaccinating against malaria
US20070071726A1 (en) * 2002-12-17 2007-03-29 Crucell Holland B.V. Recombinant viral-based malaria vaccines
WO2005063805A1 (en) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies against the amino terminus region of circumsporozoite protein prevent the onset of malaria infection
WO2005071093A2 (en) * 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
WO2006040334A1 (en) * 2004-10-14 2006-04-20 Crucell Holland B.V. Malaria prime/boost vaccines
WO2007003384A1 (en) * 2005-06-30 2007-01-11 Glaxosmithkline Biologicals Sa Anti-malaria vaccine
WO2007110409A1 (en) * 2006-03-27 2007-10-04 Crucell Holland B.V. Compositions comprising a recombinant adenovirus and an adjuvant
WO2008009650A2 (en) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccines for malaria
WO2008107370A1 (en) * 2007-03-02 2008-09-12 Glaxosmithkline Biologicals S.A. Novel method and compositions
WO2008122811A2 (en) * 2007-04-10 2008-10-16 Isis Innovation Ltd Adenoviral vectors encoding a pathogen or tumour antigen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAME J B ET AL: "STRUCTURE OF THE GENE ENCODING THE IMMUNODOMINANT SURFACE ANTIGEN ON THE SPOROZOITE OF THE HUMAN MALARIA PARASITE PLASMODIUM FALCIPARUM", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, WASHINGTON, DC, vol. 225, 1 January 1984 (1984-01-01), pages 593 - 599, XP000907559, ISSN: 0036-8075 *
SCHNEIDER J ET AL: "ENHANCED IMMUNOGENICITY FOR CD8+ T CELL INDUCTION AND COMPLETE PROTECTIVE EFFICACY OF MALARIA DNA VACCINATION BY BOOSTING WITH MODIEFIED VACCINIA VIRUS ANKARA", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 4, no. 4, 1 April 1998 (1998-04-01), pages 397 - 402, XP000739989, ISSN: 1078-8956 *
SHOTT J P ET AL: "Adenovirus 5 and 35 vectors expressing Plasmodium falciparum circumsporozoite surface protein elicit potent antigen-specific cellular IFN-gamma and antibody responses in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 26, no. 23, 2 June 2008 (2008-06-02), pages 2818 - 2823, XP022666955, ISSN: 0264-410X, [retrieved on 20080416] *
STEWART V ANN ET AL: "Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone.", INFECTION AND IMMUNITY MAY 2007, vol. 75, no. 5, May 2007 (2007-05-01), pages 2283 - 2290, XP002527574, ISSN: 0019-9567 *
TATSIS N ET AL: "Chimpanzee-origin adenovirus vectors as vaccine carriers.", GENE THERAPY MAR 2006, vol. 13, no. 5, March 2006 (2006-03-01), pages 421 - 429, XP002527576, ISSN: 0969-7128 *
ZHI YAN ET AL: "Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus.", HUMAN GENE THERAPY MAY 2006, vol. 17, no. 5, May 2006 (2006-05-01), pages 500 - 506, XP002527575, ISSN: 1043-0342 *

Also Published As

Publication number Publication date
DOP2010000164A (en) 2010-07-31
MA32003B1 (en) 2011-01-03
IL205953A0 (en) 2010-11-30
BRPI0819889A2 (en) 2015-06-16
KR20100108544A (en) 2010-10-07
MX2010006207A (en) 2010-10-04
AU2008333208A1 (en) 2009-06-11
AR069568A1 (en) 2010-02-03
TW200938633A (en) 2009-09-16
CO6300795A2 (en) 2011-07-21
CN101939438A (en) 2011-01-05
ZA201003851B (en) 2012-11-28
CA2707245A1 (en) 2009-06-11
UY31510A1 (en) 2009-08-03
JP2011505796A (en) 2011-03-03
CR11537A (en) 2010-08-18
CL2008003614A1 (en) 2010-01-15
PE20091106A1 (en) 2009-08-24
WO2009071613A2 (en) 2009-06-11
EP2227550A2 (en) 2010-09-15

Similar Documents

Publication Publication Date Title
WO2006113214A3 (en) Vaccine against pandemic strains of influenza viruses
EA201070794A1 (en) Recombinant antigens RSV
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX2012000035A (en) Recombinant rsv antigens.
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2008054540A3 (en) Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2018193063A3 (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
SI1951296T2 (en) Cell-derived viral vaccines with low levels of residual cell dna by betapropiolactone
WO2008133663A3 (en) Codon modified immunogenic compositions and methods of use
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
WO2006115843A3 (en) Nipah virus vaccines
WO2007105111A3 (en) Novel isolated and purified strains of chikungunya virus and polynucleotides and polypeptides sequences, diagnostic and immunogenical uses thereof
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
WO2007147529A3 (en) Recombinant viral vaccine
WO2012021730A3 (en) Respiratory syncytial virus (rsv) vaccine
WO2008009650A3 (en) Vaccines for malaria
WO2010068968A8 (en) Methods and compositions for use of a coccidiosis vaccine
WO2011007961A3 (en) Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitpoes
WO2009071613A3 (en) Vaccine
WO2009080715A3 (en) Vaccines for malaria
RU2016138365A (en) PCSK9 VACCINES
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
WO2005028496A3 (en) Vaccine for treatment and prevention of herpes simplex virus infection
WO2012114125A3 (en) Treatment and prevention of malaria

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126710.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857977

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 205953

Country of ref document: IL

Ref document number: 1897/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2707245

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 585894

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2010536451

Country of ref document: JP

Ref document number: 12010501294

Country of ref document: PH

Ref document number: MX/A/2010/006207

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 10070274

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2008333208

Country of ref document: AU

Date of ref document: 20081204

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2008857977

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201011537

Country of ref document: CR

Ref document number: CR2010-011537

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: DZP2010000406

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20107014859

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 2010002585

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0819889

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100604